Suliman Al-Fayoumi Selected Research

11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaene

1/2019	Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
1/2018	Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.
1/2018	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
12/2016	Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
1/2016	Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Suliman Al-Fayoumi Research Topics

Disease

5	Primary Myelofibrosis (Myelosclerosis) 01/2019 - 01/2016
2	Cytopenia 01/2018 - 12/2016
2	Neoplasms (Cancer) 12/2016 - 01/2016
2	Hypertension (High Blood Pressure) 04/2010 - 01/2010
1	Inflammation (Inflammations) 09/2018
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2018
1	Liver Diseases (Liver Disease) 01/2018
1	Non-alcoholic Fatty Liver Disease 01/2018
1	Splenomegaly 01/2018
1	Thrombocytopenia (Thrombopenia) 01/2018
1	Anemia 01/2018
1	Fibrosis (Cirrhosis) 01/2018
1	Hepatocellular Carcinoma (Hepatoma) 01/2018
1	Necrosis 01/2018
1	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2016
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2016
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2016
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 07/2014
1	Weight Loss (Weight Reduction) 07/2014
1	Cardiotoxicity 07/2014
1	Geographic Atrophy 03/2014
1	Macular Degeneration (Age-Related Maculopathy) 03/2014
1	Heart Failure 04/2010
1	Iron Overload 12/2006
1	Hemosiderosis 12/2006

Drug/Important Bio-Agent (IBA)

5	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 01/2019 - 01/2016
3	ruxolitinibIBA 01/2019 - 01/2018
2	Janus Kinase 2IBA 01/2018 - 01/2016
1	fedratinibIBA 01/2019
1	N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA 01/2019
1	Toll-Like Receptors (Toll-Like Receptor)IBA 09/2018
1	Interleukin-1 Receptor-Associated KinasesIBA 09/2018
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 09/2018
1	Interleukin-1 (Interleukin 1)IBA 09/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Telmisartan (Micardis)FDA Link 01/2018
1	Janus Kinase 1IBA 01/2018
1	AngiotensinsIBA 01/2018
1	Keratin-18 (Keratin 18)IBA 01/2018
1	Hemoglobins (Hemoglobin)IBA 01/2018
1	CytokinesIBA 01/2018
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016
1	AnthraquinonesIBA 07/2014
1	pixantrone (BBR 2778)IBA 07/2014
1	Doxorubicin (Adriamycin)FDA LinkGeneric 07/2014
1	emixustatIBA 03/2014
1	sacubitril and valsartan sodium hydrate drug combinationIBA 04/2010
1	Neprilysin (Neutral Endopeptidase)IBA 04/2010
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 04/2010
1	aliskiren FDA Link 01/2010
1	Renin InhibitorsIBA 01/2010
1	IronIBA 12/2006
1	Deferasirox FDA Link 12/2006
1	Deferoxamine (Desferal)FDA LinkGeneric 12/2006
1	Chelating AgentsIBA 12/2006

Therapy/Procedure

1	Therapeutics 01/2018
1	Intraperitoneal Injections 07/2014